Basel - Lonza Pharma & Biotech announced the establishment of a Center of Excellence for Dry Powder Inhaler (DPI) drug product development at its Bend (OR) USA site.

The DPI service offer leverages the extensive particle engineering expertise and capabilities at Lonza-Bend while incorporating Lonza site network capabilities where applicable for specific customers and/or drug programs. The core service offer is comprised of a head-to-head evaluation of particle engineering approaches (spray drying and micronization), along with capsule-based DPI formulation design and development.

As the number of candidate compounds utilizing the pulmonary and nasal delivery routes increases, particle engineering capabilities combined with formulation design expertise have become more critical in meeting target product profiles and accelerated development timelines. Lonza has more than 25 years' experience in particle engineering, formulation and encapsulation for DPI applications across a broad range of drug substance parameters and most commercially viable DPI delivery devices. This experience has been utilized in designing a service package that meets the needs of this critical first decision-making step in DPI formulation design.

Utilizing phase-appropriate assets, Lonza scientists can provide capsule-based DPI formulations for feasibility studies in as little as 12 weeks. Analytical services, including initial stability studies, are also available as part of the DPI service package. The service package can be further tailored to individual drug programs with drug substance development and supply, and services for regulatory filing submissions.

Lonza also provides customizable DPI capsules (Capsugel Zephyr capsule portfolio) designed to provide high performance and compatibility between the capsule/device and capsule/formulation.

About Lonza

At Lonza, we combine technological innovation with world class manufacturing and process excellence. Together, these enable our customers to deliver their discoveries in the healthcare, preservation, and protection sectors. We are a preferred global partner to the pharmaceutical, biotech and specialty ingredients markets. We work to prevent illness and promote a healthier world by enabling our customers to deliver innovative medicines that help treat or even cure a wide range of diseases. We also offer a broad range of microbial control solutions, which help to create and maintain a healthy environment.

Founded in 1897 in the Swiss Alps, Lonza today operates in 120 sites and offices in more than 35 countries. With approximately 15,500 full-time employees, we are built from high-performing teams and of individual employees who make a meaningful difference to our own business, as well as the communities in which we operate. The company generated sales of CHF 5.9 billion in 2019 with a CORE EBITDA of CHF 1.6 billion.

Contact:

Dr. Sanna Fowler

Tel: +41 61 316 8929

Email: sanna.fowler@lonza.com

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ('SGX-ST'). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.

(C) 2020 Electronic News Publishing, source ENP Newswire